Find information on Industry Analysis Report

Posts tagged ‘Clinical Trial’

Therapy Trends: Multiple Sclerosis

Bharat Book introduces a report ” Therapy Trends: Multiple Sclerosis ” Therapy Trends: Multiple Sclerosis disseminates critical opinion and analysis to provide premier research.

An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends.

Multiple Sclerosis: On the cusp of a treatment revolution
The year 2012 will see landmark changes in the treatment of MS. Gilenya, the first novel drug in five years, is to be joined by three new products; BG-12 from Biogen Idec, Sanofi’s Aubagio and Genzyme’s Lemtrada. These drugs will partially satisfy substantial unmet needs of convenient administration and more efficacious therapy to drive unprecedented market growth.

Driven by in-depth interviews with the world’s leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future.

Drive your strategic decision-making with inside intelligence
Therapy Trends: Multiple Sclerosis disseminates critical opinion and analysis to provide premier research.
* We cut to the heart of market-changing events and eliminate superfluous background information so you can focus on developments of greatest strategic impact and reduce your reaction time
* Our unique thought-leader selection matrix identifies the most influential KOLs in MS to deliver the perspectives vital in giving you a competitive edge, enabling informed decision-making and planning
* Detailed analysis of marketed and pipeline drugs helps you understand the products that will shape the future MS market
* KOL consensus on the future treatment algorithm offers a window into the future changes in medical evidence and clinical practice
* Uncovering KOLs’ opinions on unmet needs enables you to identify potential commercial opportunities
* Dynamic report updates evaluate the market impact of key events from KOL perspectives, allowing you to react to significant MS market developments within days of events occurring

Critical questions answered
Our MS KOLs are selected according to their level of engagement and influence within the pharmaceutical industry and their scientific standing. FirstWord’s unique KOL scoring system enables identification of KOLs with the greatest knowledge of how MS treatment will evolve and shape the future landscape.

* What are the key unmet needs? There is a high risk, high reward opportunity in the development of a therapy with efficacy for progressive subtypes. How will therapies will be positioned against each other in the future of MS treatment? Biogen’s new oral therapy BG-12 is expected to usurp the current market leaders and become the first-line therapy of choice.
* How will treatment developments play out in the near future? Biogen’s activity in broadening its robust pipeline shows its resolve in maintaining its leading position in MS.
* Is there potential for new players in the lucrative MS market? New entrants are set to capture significant share and cannibalise sales of the leading drugs.
* Where will Sanofi’s Lemtrada and Aubagio be positioned in treatment? Pricing and safety will play a large part in determining uptake of this highly effective drug
* How will the launch of biosimilars affect prescribing behavior? Pricing will be a key determinant in positioning and uptake
* How will Novartis’s Gilenya be affected by recent safety concerns? Long-term concerns have kept it from being the first line therapy.
* Will the new John Cunningham Virus test encourage earlier adoption of Tysabri? This offers the first example of personalised medicine; a trend that will aid uptake in future.

For more information kindly visit :
Therapy Trends: Multiple Sclerosis

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://bharatbook.posterous.com/
http://healthcareraj.blogspot.com/

Advertisements

Indian CRAMS Industry

Bharat Book introduces a report ” Indian CRAMS Industry ” India has become one of the favoured destinations for outsourcing contracts by drug innovators globally.

The Indian CRAMS Industry……growth trajectory commences
The Indian CRAMS industry was valued at US$3.8 bn in CY2010, accounting for approximately 6% of the US$67 bn global outsourcing market, indicating significant growth opportunities in this segment. CRAMS business consists of the CMO and CRO, of which CMO constitutes a major portion (>60%) of the overall business. The CRAMS segment, dominated by the CMO segment, starts from the phase IIB clinical trial, and continues to the off-patent stage, and includes manufacturing of intermediates, APIs and formulations. CARE Research expects the domestic CRAMS industry to grow at a CAGR of 32% over CY2010-2014E. CRAMS industry would continue to be dominated by the CMO segment forming larger portion of it, however we expect the share of CMO is likely to narrow down from ~61% in 2010; foreseeing revival in CRO segment. The CMO & CRO segment is likely to register healthy growth during 2010 – 2014E. The global CMO market is valued at US $42 bn in 2010; growing at a CAGR of 13.1% over 2007-10. It is expected to reach to US $85 bn by 2012.

Over the years Indian CRAMS players have developed expertise in manufacturing APIs and conducting high- end R&D services. India has become one of the favoured destinations for outsourcing contracts by drug innovators globally due to their product mix being skewed towards high-end research services, biologics and complex technology services, at low cost. India offers an abundant pool of professionals in the area of drug development and research chemistry with large number of pharmacists and post graduates (science) qualifying every year. Big pharma companies and global outsourcing service providers have started focusing on India for drug development and research chemistry. According to the Indian Government, by 2020 India would be one of the top five pharma innovation hubs with one out of every five to ten drugs discovered in India.

CARE Research expects stability in the margins of Indian pharma sector till FY13E based on consistent demand for generic products from regulated markets especially the US. Hence, CRAMS players would be forced to keep the prices in control and with their higher input costs, depreciation and plant maintenance costs they would witness pressure on their margins till H1FY13. Also, the pricing of contracts for the generic drugs is lower compared to patented drugs which further leads to margin reduction. The EBIDTA margins of players under our coverage in Q3FY12 declined by around 330 bps YoY and around 150bps QoQ.

As per CARE Research estimates, the margins of CRAMS company analysed by us would remain under pressure and decline in the range of 150-200bps until H1FY13 whereby most of the capex would be done and would stabilize thereafter. CRAMS players with their advanced technical skills and capabilities would focus on higher export orders for augmenting their margins.

A large portion of the CRAMS activity is outsourced to India and China as they are comparatively lower cost destinations. However, India enjoys a better position compared to China in key areas like chemistry and technology skill, quality of products & services offered and meeting the regulatory body requirements. China is known for low labour costs as compared to any other country, however India scores in terms of quality and intelligence. India has more number of FDA approved plants compare to China. Also, the number of DMF filings in India (50% of the overall DMF filing) is much more compared to China. Hence, CARE Research doesn’t expect China to be a major threat to Indian CRAMS industry.

For more information kindly visit :
Indian CRAMS Industry

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://bharatbook.posterous.com/
http://healthcareraj.blogspot.com/

Healthcare Cloud Computing (Clinical, EMR, SaaS, Private, Public, Hybrid) Market – Global Trends, Challenges, Opportunities & Forecasts (2012 – 2017)

Technologies in the healthcare IT industry are converging with time and are far outpacing the legacy systems used by hospitals and healthcare providers. Pronouncements by various countries such as American Recovery and Reinvestment Act of 2009 (ARRA) laid down by the U.S. government are encouraging businesses in the healthcare industry to utilize certain applications of electronic records. Recently, cloud technology has started replacing these legacy systems and offers easier and faster access to this data as defined by the way it is stored i.e. public, private or hybrid.

Cloud computing offers significant benefits to the healthcare sector; Doctor’s clinics, hospitals, and health clinics require quick access to computing and large storage facilities which are not provided in the traditional settings, moreover healthcare data needs to be shared across various settings and geographies which further burdens the healthcare provider and the patient causing significant delay in treatment and loss of time. Cloud caters to all these requirements thus providing the healthcare organizations an incredible opportunity to improve services to their customers, the patients, to share information more easily than ever before, and improve operational efficiency at the same time. The flip side of this advantage is that healthcare data has specific requirements such as security, confidentiality, availability to authorized users, traceability of access, reversibility of data, and long-term preservation. Hence, cloud vendors need to account for all these while conforming to regulations such as HIPAA and Meaningful use.

All the above factors bring the market for cloud computing to grow at a CAGR of 20.5% from 2010 to 2017 in healthcare. Although cloud computing offers significant advantages to HCOs and other stakeholders, it has set of restraints. Security of patient information, interoperability and compliance with government regulations are some of the factors which are slowing down this market.

Cloud technology has been adopted only in certain regions of the world, the majority share being held by the developed nations. The geographies studied include North America, Europe, Asia, and ROW. North America accounts for the lion’s share in the cloud computing market with U.S. being the largest contributor to this region.

The healthcare cloud computing market is a fragmented one with no player occupying a share more than 5%. A few players in this market are CareCloud (U.S.), Carestream Health, Inc. (U.S.), Merge Healthcare, Inc. (U.S.), GE Healthcare (U.K.), and Agfa Healthcare (Belgium).

Find More:

Healthcare Cloud Computing (Clinical, EMR, SaaS, Private, Public, Hybrid) Market – Global Trends, Challenges, Opportunities & Forecasts (2012 – 2017)

Tag Cloud